Download PDF

Diabetologia

, Volume 18, Issue 3, pp 187–191 | Cite as

Somatostatin infusion in liver cirrhosis: Glucagon control of glucose homeostasis

  • A. V. Greco
  • L. Altomonte
  • G. Ghirlanda
  • A. G. Rebuzzi
  • R. Manna
  • A. Bertoli
Originals
Received:
Revised:

Summary

In order to evaluate the role of glucagon in blood glucose homeostasis in liver cirrhosis, ten normal subjects and ten cirrhotic patients were infused with somatostatin (500 μg/h for 5 h) with and without glucagon (3 mg/kg/h) administration. Somatostatin infusion brought about a fall in plasma glucose both in normal (37%) and cirrhotic (41%) subjects in the first 90 minutes. In normal subjects, this was followed by a rise in plasma glucose (147±2 mg/dl at 5 h), while in cirrhotics no rise in plasma glucose was observed (50±1 mg/dl at 5 h). Plasma insulin and glucagon levels were suppressed in both normal and cirrhotic subjects. Addition of glucagon to the somatostatin infusion caused a two fold rise in plasma glucose level to 183±12 mg/dl at 4 h in normal subjects; a much smaller increase was found in the cirrhotic group (105±3 mg/dl at 4 h). When the infusion was stopped, plasma glucose fell both in normal and cirrhotic subjects (102±14 and 87±2 mg/dl at 6 h respectively). Subsequently, hyperglucagonaemia recurred in the cirrhotic patients (319 ±31 pg/ml). A rebound of plasma insulin was observed in normal subjects (47±8 μU/ml) which did not occur in the cirrhotics (16±2 μU/ml). Thus when both insulin and glucagon were suppressed by somatostatin infusion, euglycaemia occurred in cirrhotic subjects only when glucagon concentration was restored exogenously. We conclude that glucagon is important in glucose homeostasis in patients with liver cirrhosis.

Key words

Cirrhosis somatostatin glucagon plasma glucose glucose intolerance insulin 
Download to read the full article text

References

  1. 1.
    Alberti K G M M, Christensen N J, Christensen S E, Prange Hansen Aa, Iversen J, Lundbaek K, Seyer-Hansen K, Ørskov H (1973) Inhibition of insulin secretion by somatostatin. Lancet II: 1299–1301Google Scholar
  2. 2.
    Alford F P, Bloom S R, Nabarro J D N, Hall R, Besser G M, Coy D H, Kastin A J, Schally A V (1974) Glucagon control of fasting glucose in man. Lancet II: 974–976Google Scholar
  3. 3.
    Altszuler N, Gottlieb B, Hampshire J (1976) Interaction of somatostatin, glucagon, and insulin on hepatic glucose output in the normal dog. Diabetes 25: 116–121Google Scholar
  4. 4.
    Berger D, Crowther R C, Floyd J C Jr, Pek S, Fayans S S (1978) Effect of age on fasting plasma levels of pancreatic hormones in man. J Clin Endocrinol Metab 47: 1183–1189Google Scholar
  5. 5.
    Bloomgarden Z T, Liljenquist J E, Cherrington A D, Rabinowitz D (1978) Persistent stimulatory effect of glucagon on glucose production despite downregulation. J Clin Endocrinol Metab 47: 1152–1155Google Scholar
  6. 6.
    Cherrington A D, Chiasson J L, Liljenquist J E, Jennings A S, Keller U, Lacy W W (1976) The role of insulin and glucagon in the regulation of basal glucose production in the postabsorptive dog. J Clin Invest 58: 1407–1418Google Scholar
  7. 7.
    Cherrington A D, Lacy W W, Chiasson J L (1978) Effect of glucagon on glucose production during insulin deficiency in the dog. J Clin Invest 62: 664–677Google Scholar
  8. 8.
    De Vane G W, Siler T M, Yen S S C (1974) Acute suppression of insulin and glucose levels by synthetic somatostatin in noral human subjects. J Clin Endocrinol Metab 38: 913–915Google Scholar
  9. 9.
    Gerich J E, Lorenzi M, Hane S, Gustafson G, Guillemin R, Forsham P H (1975) Evidence for a physiologic role of pancreatic glucagon in human glucose homeostasis: studies with somatostatin. Metabolism 24: 175–182Google Scholar
  10. 10.
    Gerich J E, Lorenzi M, Schneider V, Karam J H, Rivier J, Guillemin R, Forsham P H (1974) Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus. Pathophysiologic and therapeutic implications. N Engl J Med 291: 544–547Google Scholar
  11. 11.
    Greco A V, Fedeli G, Ghirlanda G, Manna R, Patrono C (1974) Behavior of pancreatic glucagon, insulin and HGH in liver cirrhosis, after arginine and i. v. glucose. Acta Diabetol Lat 11: 330–339Google Scholar
  12. 12.
    Hales C N, Randle P J (1963) Immunoassay of insulin with insulin-antibody precipitate. Biochem J 88: 137–146Google Scholar
  13. 13.
    Iversen J (1974) Inhibition of pancreatic glucagon release by somatostatin. Scand J Clin Lab Invest 33: 125–129Google Scholar
  14. 14.
    Liljenquist J E, Chiasson J L, Cherrington A D, Keller U, Jennings A S, Bomboy J D, Lacy W W (1976) An important role for glucagon in the regulation of glucose production in vivo. Metabolism 25 (Suppl 1): 1371–1373Google Scholar
  15. 15.
    Liljenquist J E, Mueller G L, Cherrington A D, Keller U, Chiasson J L, Perry J M, Lacy W W, Rabinowitz D (1977) Evidence for a important role of glucagon in the regulation of hepatic glucose production in normal man. J Clin Invest 59: 369–374Google Scholar
  16. 16.
    Marco J, Diego J, Villanueva M L, Diaz-Fierros M, Valverde I, Segovia J M (1973) Elevated plasma glucagon levels in cirrhosis of the liver. N Engl J Med 289: 1107–1111Google Scholar
  17. 17.
    Mortimer C H, Carr D, Lind T, Bloom S R, Mallinson C N, Schally A V, Tunbridge W M G, Yeomans L, Coy D H, Kastin A, Besser G M, Hall R (1974) Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin and growth hormone in normal, diabetic, acromegalic, and hypopuitary patients. Lancet I: 697–701Google Scholar
  18. 18.
    Perez G, Trimarco B, Ungaro B, Rengo F, Sacca' L (1978) Glucoregulatory response to insulin-induced hypoglycemia in Laennec's cirrhosis. J Clin Endocrinol Metab 46: 778–783Google Scholar
  19. 19.
    Sherwin R S, Fisher M, Bessoff J, Snyder N, Hendler R, Conn H O, Felig P (1978) Hyperglucagonemia in cirrhosis: altered secretion and sensitivity to glucagon. Gastroenterology 74: 1224–1228Google Scholar
  20. 20.
    Sherwin R, Joshi P, Hendler R, Felig P, Conn H O (1974) Hyperglucagonemia in Laennec's cirrhosis: the role of portalsystemic shunting. N Engl J Med 290: 239–242Google Scholar
  21. 21.
    Sherwin R S, Tamborlane W, Hendler R, Sacca' L, De Fronzo R A, Felig P (1977) Influence of glucagon replacement on the hyperglycemic and hyperketonemic response to prolonged somatostatin infusion in normal man. J Clin Endocrinol Metab 45: 1104–1107Google Scholar
  22. 22.
    Shurberg J L, Resnick R H, Koff R S, Ros E, Baum R A, Pallotta J A (1977) Serum lipids, insulin, and glucagon after portacaval shunt in cirrhosis. Gastroenterology 72: 301–304Google Scholar
  23. 23.
    Sperling M A, Graiwer L A, Leake R, Fisher D A (1976) Role of glucagon in perinatal glucose homeostasis. Metabolism 25 (Suppl 1): 1385–1386Google Scholar
  24. 24.
    Unger R H, Eisentraut A M, McCall M S, Madison L L (1962) Measurements of endogenous glucagon in plasma and the influence of blood glucose concentration upon its secretion. J Clin Invest 41: 682–689Google Scholar
  25. 25.
    Wahren J, Efendic S, Luft R, Hagenfeldt L, Björkman O, Felig P (1977) Influence of somatostatin on splanchnic glucose in postabsorptive and 60-hour fasted humans. J Clin Invest 59: 299–307Google Scholar

Copyright information

© Springer-Verlag 1980

Authors and Affiliations

  • A. V. Greco
    • 1
  • L. Altomonte
    • 1
  • G. Ghirlanda
    • 1
  • A. G. Rebuzzi
    • 1
  • R. Manna
    • 1
  • A. Bertoli
    • 1
  1. 1.Istituto di Patologia MedicaCatholic UniversityRomeItaly

Personalised recommendations